Cited 8 times in
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2023-11-28T03:32:46Z | - |
dc.date.available | 2023-11-28T03:32:46Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196846 | - |
dc.description.abstract | Purpose: Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced non-small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to predict outcomes. Patients and methods: This was a retrospective, exploratory analysis of two phase III trials [AURA3 (NCT02151981), FLAURA (NCT02296125)]. All patients had EGFR mutation-positive (EGFRm; ex19del or L858R) advanced NSCLC; AURA3 also included T790M-positive NSCLC. Osimertinib (FLAURA, AURA3), or comparator EGFR-tyrosine kinase inhibitor (EGFR-TKI; gefitinib/erlotinib; FLAURA), or platinum-based doublet chemotherapy (AURA3) was given. Plasma EGFRm was analyzed at baseline and Weeks 3/6 by droplet digital PCR. Outcomes were assessed by detectable/non-detectable baseline plasma EGFRm and plasma EGFRm clearance (non-detection) at Weeks 3/6. Results: In AURA3 (n = 291), non-detectable versus detectable baseline plasma EGFRm had longer median progression-free survival [mPFS; HR, 0.48; 95% confidence interval (CI), 0.33-0.68; P < 0.0001]. In patients with Week 3 clearance versus non-clearance (n = 184), respectively, mPFS (months; 95% CI) was 10.9 (8.3-12.6) versus 5.7 (4.1-9.7) with osimertinib and 6.2 (4.0-9.7) versus 4.2 (4.0-5.1) with platinum-pemetrexed. In FLAURA (n = 499), mPFS was longer with non-detectable versus detectable baseline plasma EGFRm (HR, 0.54; 95% CI, 0.41-0.70; P < 0.0001). For Week 3 clearance versus non-clearance (n = 334), respectively, mPFS was 19.8 (15.1 to not calculable) versus 11.3 (9.5-16.5) with osimertinib and 10.8 (9.7-11.1) versus 7.0 (5.6-8.3) with comparator EGFR-TKI. Similar outcomes were observed by Week 6 clearance/non-clearance. Conclusions: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Association for Cancer Research | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jhanelle E Gray | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Geoffrey R Oxnard | - |
dc.contributor.googleauthor | Frances A Shepherd | - |
dc.contributor.googleauthor | Fumio Imamura | - |
dc.contributor.googleauthor | Ying Cheng | - |
dc.contributor.googleauthor | Isamu Okamoto | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Meng-Chih Lin | - |
dc.contributor.googleauthor | Yi-Long Wu | - |
dc.contributor.googleauthor | Margarita Majem | - |
dc.contributor.googleauthor | Oliver Gautschi | - |
dc.contributor.googleauthor | Michael Boyer | - |
dc.contributor.googleauthor | Krishna C Bulusu | - |
dc.contributor.googleauthor | Aleksandra Markovets | - |
dc.contributor.googleauthor | J Carl Barrett | - |
dc.contributor.googleauthor | Rachel Hodge | - |
dc.contributor.googleauthor | Astrid McKeown | - |
dc.contributor.googleauthor | Ryan J Hartmaier | - |
dc.contributor.googleauthor | Juliann Chmielecki | - |
dc.contributor.googleauthor | Vassiliki A Papadimitrakopoulou | - |
dc.contributor.googleauthor | Suresh S Ramalingam | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-22-3146 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 37379430 | - |
dc.identifier.url | https://aacrjournals.org/clincancerres/article/29/17/3340/728537/Early-Clearance-of-Plasma-Epidermal-Growth-Factor | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 3340 | - |
dc.citation.endPage | 3351 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.29(17) : 3340-3351, 2023-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.